Therapeutic Area

Endocrinology

Corcept is committed to unlocking the potential of cortisol modulation to revolutionize treatment of serious diseases. This site contains scientific resources and information developed or curated by Corcept for healthcare professionals.

2026

Poster

Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease

American Society for Preventative Cardiology

2026

Poster

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

Heart in Diabetes

2026

Poster

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study

Annual Meeting of The Endocrine Society

2026

2025

Presentation

A New Cause of Diabetes That Affects ~1.25M Americans: Who Woulda Thought?

American Diabetes Association

2025

Presentation

Design of the CATALYST Trial and Prevalence Results

American Diabetes Association

2025

Presentation

Final Results of the CATALYST Trial

American Diabetes Association

2025

2024

Presentation

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

European Congress of Endocrinology

2024

Presentation

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Heart in Diabetes

2024

Poster

Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond

Heart in Diabetes

2024

2023

Presentation

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

The Italian Society of Endocrinology

2023

Poster

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

Annual Meeting of The Endocrine Society

2023

Poster

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Annual Meeting of The Endocrine Society

2023

2022

Poster

Impact of mifepristone on liver function and liver steatosis in patients with Cushing syndrome

Annual Meeting of The Endocrine Society

2022

Poster

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome

Annual Meeting of The Endocrine Society

2022

Poster

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome

European Congress of Endocrinology

2022

2021

Poster

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production

Annual Meeting of The Endocrine Society

2021

Poster

Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search

American Association of Clinical Endocrinology

2021

Poster

Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis

American Association of Clinical Endocrinology

2021

2020

Poster

GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

Annual Meeting of The Endocrine Society

2020

Poster

A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Patients With Hypercortisolism Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

European Congress of Endocrinology

2020

Poster

Excess Glucocorticoid Activity May Suppress Tumor Immune Activity in Adrenocortical Carcinoma

European Congress of Endocrinology

2020

2019

Poster

A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients With Cushing Syndrome (GRACE Study)

Annual Meeting of The Endocrine Society

2019

Poster

Sustained Clinical Improvement After Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism

Annual Meeting of The Endocrine Society

2019

Poster

Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients

Annual Meeting of The Endocrine Society

2019

2018

Poster

Mifepristone therapy prior to pituitary surgery in Cushing disease prevented need for long-term glucocorticoid replacement

Annual Meeting of The Endocrine Society

2018

Poster

A curious case of biochemical and clinical remission after treatment with mifepristone, a glucocorticoid receptor antagonist

Annual Meeting of The Endocrine Society

2018

Poster

Administration of localized progestin before mifepristone treatment may prevent endometrial thickening and breakthrough bleeding

Annual Meeting of The Endocrine Society

2018

2017

Poster

Mifepristone reduced u500 insulin usage in a patient with Cushing disease and normalized concomitant fatty liver disease and retinopathy

American Association of Clinical Endocrinology

2017

Poster

Screening of diabetic patients using u500 insulin uncovers a high percentage of undiagnosed hypercortisolism consistent with Cushing syndrome

American Association of Clinical Endocrinology

2017

Poster

Improving glycemic control with mifepristone in Cushing syndrome patients may lead to significant weight-loss

American Association of Clinical Endocrinology

2017

2016

Poster

Immediate and sustained improvements in a cushing’s syndrome patient with primary macronodular adrenal hyperplasia treated with mifepristone

American Association of Clinical Endocrinology

2016

Poster

Prevention of secondary adrenal insufficiency with presurgical use of mifepristone in patients with autonomous cortisol-secreting adenomas

American Association of Clinical Endocrinology

2016

Poster

Short-Term Mifepristone Treatment Improved Preoperative Clinical Status in a High-Risk Patient With Unexpected Normalization of Liver Enzymes

Annual Meeting of The Endocrine Society

2016

2015

Poster

Pre-surgical Use of Mifepristone for Ectopic Cushing’s in a High-Risk Bilateral Adrenalectomy Candidate

Annual Meeting of The Endocrine Society

2015

Poster

Mifepristone for the Successful Treatment of Cushing’s Syndrome After Multiple Failed Interventions

Annual Meeting of The Endocrine Society

2015

Poster

Marked Improvement in Liver Enzymes During Medical Therapy With Mifepristone for Cushing’s Syndrome

Annual Meeting of The Endocrine Society

2015

2014

Poster

Case Presentation: Improved Activities of Daily Living, Normal Mood and Quality of Life: 4 Years of Treatment Data in a Pre-menopausal Woman with Cushing's Disease

Other

2014

2013

Poster

Quality of Life Changes in Participants of the SEISMIC Extension Trial in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Annual Meeting of The Endocrine Society

2013

Poster

Using Mifepristone to Differentiate Cushing's Disease From Cushing's Syndrome

Annual Meeting of The Endocrine Society

2013

Abstract

Abstract: Using Mifepristone to Differentiate Cushing's Disease From Cushing's Syndrome

Other

2013

2012

Poster

Predicting and Managing Hypertension and Hypokalemia in Cushing's Syndrome During Mifepristone Therapy

Other

2012

Abstract

Abstract: Mifepristone Improves Global Clinical Status in Patients With Cushing's Syndrome: Results from the SEISMIC Study

Other

2012

Publication

Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study

2026

Publication

Relacorilant or surgery improved hemostatic markers in Cushing syndrome

2025

Publication

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment

2025

Publication

Identification of Endogenous Hypercortisolism and the Effect of Mifepristone Treatment in Patients With Difficult-to-Manage Diabetes: A Case Series

2025

Publication

Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

2024

Publication

Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone

2024

Publication

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

2022

Publication

Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition

2022

Publication

When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis

2021

Publication

Hidden hypercortisolism: a too frequently neglected clinical condition

2021

Publication

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

2021

Publication

Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients

2019

Publication

Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone

2017

Publication

Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome

2016

Publication

Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis

2016

Publication

Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study

2016

Publication

Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome

2015

Publication

Mifepristone and Cushing syndrome: A commentary

2015

Publication

Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study

2014

Publication

Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study

2014

Publication

Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas

2014

Publication

A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone

2013

Publication

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome

2012

Publication

Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)

2001

Publication

Persistent Weight Loss in Patients Treated With Mifepristone for Cushing's Syndrome: Results From the SEISMIC & Long-Term Extension Studies

2015

Publication

Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects.

2013

Publication

Investigating Endogenous Hypercortisolism Prevalence in a US Population with Resistant Hypertension: MOMENTUM Rationale and Design

2026

Publication

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

2025

Publication

Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases

2021

Publication

Clinical Management of patients with Cushing Syndrome treated with mifepristone: consensus recommendations

2020

Publication

Assessment of Safety,Tolerability,Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study

2018

Publication

Global clinical response in Cushing’s syndrome patients treated with mifepristone

2014

Disease State Resource

Download disease state slide decks on hypercortisolism

Educational Program

CASCADE, an expert-led, disease state educational program on hypercortisolism

Compassionate Use

Corcept offers access to investigational medications through clinical trials or compassionate use for eligible patients facing serious or life-threatening diseases who may not qualify for trials or have alternative treatment options

Medical Education Grants

Corcept provides grant funding to eligible organizations to support independent medical and patient education, and other activities intended to advance knowledge and patient care

Endocrinology

Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease

Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study

Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol <1.2, 1.2–1.8, and >1.8 μg/dL: Results From the MOMENTUM Study

A New Cause of Diabetes That Affects ~1.25M Americans: Who Woulda Thought?

Design of the CATALYST Trial and Prevalence Results

Final Results of the CATALYST Trial

Open-label Extension Study Evaluating the Safety and Efficacy of Long-term Use of Relacorilant in Patients With Endogenous Hypercortisolism (Cushing Syndrome): Interim Analysis Results

Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study

Hypercortisolism Impact on Hypertension and Hyperglycemia and Beyond

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

Impact of Surgery or Medical Treatment With the Selective Glucocorticoid Receptor Modulator Relacorilant on Hypercoagulopathy in Patients With Cushing Syndrome

A Phase 4 Study of Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies, Assessing Prevalence and Treatment with Mifepristone

Impact of mifepristone on liver function and liver steatosis in patients with Cushing syndrome

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome

Favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with Cushing syndrome

Relacorilant With Pembrolizumab: A Phase 1b, Open-Label Study of a Selective Glucocorticoid Receptor Modulator Combined With a Checkpoint Inhibitor for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production

Prevalence of Hypercortisolism in Patients With Adrenal Adenoma(s) and Type 2 Diabetes Mellitus: Findings From an Electronic Medical Records (EMR) Search

Use of Mifepristone in a Hypercortisolemic Patient With End-Stage Renal Disease on Hemodialysis

GRADIENT: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of a Selective Glucocorticoid Receptor Modulator, Relacorilant, in Patients With Autonomous Cortisol Secretion Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

A Double-Blind, Randomized, Placebo-Controlled Phase 3 Study to Assess the Efficacy and Safety of Relacorilant, a Selective Glucocorticoid Receptor Modulator, in Patients With Hypercortisolism Due to Cortisol-Secreting Adrenal Adenoma(s)/Hyperplasia

Excess Glucocorticoid Activity May Suppress Tumor Immune Activity in Adrenocortical Carcinoma

A Randomized-Withdrawal, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Selective Glucocorticoid Receptor Antagonist, Relacorilant, in Patients With Cushing Syndrome (GRACE Study)

Sustained Clinical Improvement After Discontinuation of Mifepristone: Unexpected Remission of Hypercortisolism

Anticipating Hypokalemia in Patients With ACTH-Dependent Cushing Syndrome Treated With Mifepristone: Utilization of Cortisol and ACTH Levels to Identify At-Risk Patients

Mifepristone therapy prior to pituitary surgery in Cushing disease prevented need for long-term glucocorticoid replacement

A curious case of biochemical and clinical remission after treatment with mifepristone, a glucocorticoid receptor antagonist

Administration of localized progestin before mifepristone treatment may prevent endometrial thickening and breakthrough bleeding

Mifepristone reduced u500 insulin usage in a patient with Cushing disease and normalized concomitant fatty liver disease and retinopathy

Screening of diabetic patients using u500 insulin uncovers a high percentage of undiagnosed hypercortisolism consistent with Cushing syndrome

Improving glycemic control with mifepristone in Cushing syndrome patients may lead to significant weight-loss

Immediate and sustained improvements in a cushing’s syndrome patient with primary macronodular adrenal hyperplasia treated with mifepristone

Prevention of secondary adrenal insufficiency with presurgical use of mifepristone in patients with autonomous cortisol-secreting adenomas

Short-Term Mifepristone Treatment Improved Preoperative Clinical Status in a High-Risk Patient With Unexpected Normalization of Liver Enzymes

Pre-surgical Use of Mifepristone for Ectopic Cushing’s in a High-Risk Bilateral Adrenalectomy Candidate

Mifepristone for the Successful Treatment of Cushing’s Syndrome After Multiple Failed Interventions

Marked Improvement in Liver Enzymes During Medical Therapy With Mifepristone for Cushing’s Syndrome

Case Presentation: Improved Activities of Daily Living, Normal Mood and Quality of Life: 4 Years of Treatment Data in a Pre-menopausal Woman with Cushing's Disease

Quality of Life Changes in Participants of the SEISMIC Extension Trial in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome

Using Mifepristone to Differentiate Cushing's Disease From Cushing's Syndrome

Abstract: Using Mifepristone to Differentiate Cushing's Disease From Cushing's Syndrome

Predicting and Managing Hypertension and Hypokalemia in Cushing's Syndrome During Mifepristone Therapy

Abstract: Mifepristone Improves Global Clinical Status in Patients With Cushing's Syndrome: Results from the SEISMIC Study

Efficacy and Safety of Relacorilant for the Treatment of Patients With Cushing’s Syndrome (GRACE): A Multicentre, Phase 3, Double-Blind, Placebo-Controlled, Randomised-Withdrawal Study

Relacorilant or surgery improved hemostatic markers in Cushing syndrome

Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment

Identification of Endogenous Hypercortisolism and the Effect of Mifepristone Treatment in Patients With Difficult-to-Manage Diabetes: A Case Series

Relacorilant, a Selective Glucocorticoid Receptor Modulator in Development for the Treatment of Patients With Cushing Syndrome, Does Not Cause Prolongation of the Cardiac QT Interval

Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone

Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition

When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis

Hidden hypercortisolism: a too frequently neglected clinical condition

Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study

Hypercortisolism in Newly Diagnosed Type 2 Diabetes: A Prospective Study of 384 Newly Diagnosed Patients

Evaluation of evidence of adrenal insufficiency in trials of normocortisolemic patients treated with mifepristone

Mifepristone improves octreotide efficacy in resistant ectopic Cushing’s syndrome

Prevalence of hypercortisolism in type 2 diabetes patients: a systematic review and meta-analysis

Prevalence of subclinical hypercortisolism in type 2 diabetic patients from the Rio de Janeiro Type 2 Diabetes Cohort Study

Association between mifepristone dose, efficacy, and tolerability in patients with Cushing syndrome

Mifepristone and Cushing syndrome: A commentary

Long-Term Follow-Up in Adrenal Incidentalomas: An Italian Multicenter Study

Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study

Cortisol as a Marker for Increased Mortality in Patients with Incidental Adrenocortical Adenomas

A new therapeutic approach in the medical treatment of Cushing’s syndrome: glucocorticoid receptor blockade with mifepristone

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome

Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486)

Persistent Weight Loss in Patients Treated With Mifepristone for Cushing's Syndrome: Results From the SEISMIC & Long-Term Extension Studies

Improvement in insulin sensitivity during mifepristone treatment of Cushing syndrome: early and late effects.

Investigating Endogenous Hypercortisolism Prevalence in a US Population with Resistant Hypertension: MOMENTUM Rationale and Design

Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes

Mifepristone as Bridge or Adjunct Therapy in the Management of Challenging Cushing Disease Cases

Clinical Management of patients with Cushing Syndrome treated with mifepristone: consensus recommendations

Assessment of Safety,Tolerability,Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double-Blind, Randomized, Placebo-Controlled Phase 1 Clinical Study

Global clinical response in Cushing’s syndrome patients treated with mifepristone

Download disease state slide decks on hypercortisolism

CASCADE, an expert-led, disease state educational program on hypercortisolism

Corcept offers access to investigational medications through clinical trials or compassionate use for eligible patients facing serious or life-threatening diseases who may not qualify for trials or have alternative treatment options

Corcept provides grant funding to eligible organizations to support independent medical and patient education, and other activities intended to advance knowledge and patient care

You are leaving Corcept Medical